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Abstract
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Velocardiofacial syndrome (VCFS) is caused by a micro-deletion of over 40 genes at the q11.2
locus of chromosome 22 and is a risk factor for the development of schizophrenia and other
psychiatric disorders. COMT, one of the genes located in the deleted region, has been considered
as a major candidate gene for genetic susceptibility in psychiatric diseases. Its functional
polymorphism Val108/158Met has been shown to affect prefrontal function and working memory
and has been associated with emotional dysregulation. We utilized a functional magnetic
resonance imaging (fMRI) event-related paradigm to asses COMT genotype and gendermoderated effects on the neural activation that are elicited by viewing emotionally salient images
charged with pleasant, unpleasant, and neutral content. Since estrogen down-regulates COMT
activity resulting in lower COMT activity in women than men, we hypothesized an allele-bygender interaction effect on neural activation. Participants included 43 VCFS individuals (Val/
Male=9, Val/Female=17, Met/Male=9, Met/Female=8). We observed a gender effect on
processing positive emotions, in that girls activated the cingulate gyrus more than boys. We
further observed a significant gender-by-allele interaction effect on neural function specific to the
frontal lobe during the processing of pleasant stimuli, and specific to limbic regions during the
processing of unpleasant stimuli. Our results suggest that in VCFS, the effect of the COMT
Val108/158Met polymorphism is moderated by gender during the processing of emotional stimuli
and could contribute to the understanding of the way in which this COMT polymorphism affects
vulnerability to neuropsychiatric disorders.
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1. Introduction
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Velocardiofacial syndrome (VCFS) is caused by a micro-deletion of over 40 genes at the
q11.2 locus of chromosome 22. The 22q11.2 micro-deletion occurs with a frequency of
about 1 in 4000 live births and is therefore the most common micro-deletion syndrome
(Botto, L.D. et al. 2003). VCFS is characterized by a seemingly heterogeneous set of
symptoms which frequently include cardiac anomalies, cleft palate, learning disabilities, and
mental retardation (Shprintzen, R.J. et al. 1978). Additionally, VCFS confers a significantly
higher risk, relative to the general population, for the development of schizophrenia and
other psychiatric disorders, including ADHD, anxiety, depression, and obsessive compulsive
disorder. The prevalence of schizophrenia in the VCFS population is estimated at between
20 to 30 percent, as compared to a 1 percent incidence in the general population (Murphy,
K.C. et al. 1999; Green, T. et al. 2009). Although the mechanism behind the development of
schizophrenia remains unclear, a number of genes in the 22q11.2 region have been
implicated as possible susceptibility loci believed to play a role (Berrettini, W.H. 2000;
McGuffin, P. et al. 2003; Owen, M.J. et al. 2004).
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Catechol O-Methyltransferase (COMT) is one such candidate gene. COMT is an enzyme
responsible for the synaptic catabolism of catecholamines, including dopamine, epinephrine,
and norepinephrine. Two distinct functional forms of COMT exist as a result of a single
nucleotide polymorphism (SNP) at codon 108/158. The functional polymorphism arises as a
result of a G to A missense mutation. This SNP results in the substitution of Methionine for
Valine (Val108/158Met). While the Val108/158 allele is stable at normal body temperatures,
the Met108/158 allele is thermolabile and is therefore only about one-fourth as
enzymatically active. Accordingly, the Val108/158 allele is more efficient than the Met
allele, which degrades dopamine more slowly and thus allows the dopamine to remain
active, in its signaling form, for a longer period of time within neural synapses (Lotta, T. et
al. 1995). We know less about the effect of the Val108/158Met polymorphism on the
noradrenergic (as opposed to dopaminergic) system (DeRosse, P. et al. 2006). However, it
has been demonstrated that variability in this polymorphism affects response to psychoactive
substances that target the noradrenergic system (Szegedi, A. et al. 2005). Noradrenergic
neurons project to numerous brain regions involved in processing affective stimuli (Moore,
R.Y. and Bloom, F.E. 1979; Heinz, A. and Smolka, M.N. 2006) such as the amygdala,
hippocampus, and cingulate, and norepinephrine is strongly implicated in emotion memory
and regulation (Berridge, C.W. and Waterhouse, B.D. 2003; Hurlemann, R. et al. 2005).
Patients with VCFS have only one copy of the COMT gene and, therefore, may have higher
baseline levels of catecholamines than the general public. Although several linkage and
association studies have demonstrated a relationship between COMT and psychiatric
diseases, these studies as a whole have been short of conclusive. Investigations into the
relationship between COMT genotype and cognitive functioning have proven to be more
successful in generating consistent results.
In an animal study (Gogos, J.A. et al. 1998), COMT knockout mice expressed a sexually
dimorphic change in the amount of dopamine present in the frontal cortex. Male knockout
mice experienced a 2-3 fold increase in the amount of dopamine present in the frontal
cortex, whereas female mice of the same COMT genotype did not experience such an
increase. This gender mediated alteration in dopamine levels was attributed to the hormonal
down-regulation of COMT by estrogens (Cohn, C.K. and Axelrod, J. 1971). Sexually
dimorphic behavioral phenotypes were also noted in that COMT knockout females
behaviorally demonstrated an altered emotional reactivity, which speaks to the role of
COMT in some aspects of emotionality in this animal model (Gogos, J.A. et al. 1998).
Several human studies have strengthened the support for the effect of epigenetic
determination of COMT activity by estrogen. A number of these studies impute the
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Val108/158Met polymorphism in the increased incidence of anxiety and depression in
females (Hosak, L. 2007; Harrison, P.J. and Tunbridge, E.M. 2008).

NIH-PA Author Manuscript

Although the direct association between COMT and schizophrenia has not been established
definitively, dopaminergic and noradrenergic neurotransmission is of crucial importance to
neural circuits involved in endophenotypes for schizophrenia, including disrupted affective
arousal, working memory, and executive function. As such, it is more likely that the
Val108/158Met polymorphism will have a more robust effect on the underlying neural
functioning associated with psychosis, than with the psychiatric disease itself
(Lewandowski, K.E. 2007). If COMT has a stronger relationship to neural activation than to
observable behaviors, a fMRI investigation should prove to be an effective tool in
understanding the genotypic effect of COMT on emotional processing (Hariri, A.R. and
Weinberger, D.R. 2003).
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Several imaging studies thus far have linked COMT genotype with differential neural
activation elicited by emotional processing (Smolka, M.N. et al. 2005; Heinz, A. and
Smolka, M.N. 2006). Heinz and Smolka (2005) have demonstrated that, in the general
population, the Met108/158 allele is significantly positively correlated to the amount of
reactivity displayed in the amygdala and other limbic locations. The same dose dependent
Met allele interaction with limbic reactivity was replicated by Drabant et al. (2006). The
hyper-activation of limbic structures was described, by both authors, as a possible
contributing factor to the emotional dysregulation and lower emotional resilience that had
been previously observed in those individuals who were homozygous for the Met108/158
allele.
A recent fMRI investigation of healthy subjects from the general population utilized a facial
affect recognition task in order to further elucidate the interaction between gender and
COMT genotype on brain activation during emotion processing (Kempton, M.J. et al. 2009).
The study found that females showed a greater task-related activation in the left amygdala
and temporal pole when compared with males. Additionally, the authors observed that Val
homozygotes showed a larger magnitude of neural activation than Met homozygotes,
particularly in females.
Previous findings from our work on children with VCFS have shown that the COMT
Val108/158Met polymorphism also affects prefrontal tissue volumes in a gender-specific
fashion (Kates, W.R. et al. 2006a). In this study, females hemizygous for the Met108/158
allele and males hemizygous for the Val108/158 allele were found to have larger dorsal
prefrontal volumes and smaller orbital frontal volumes than females hemizygous for the
Val108/158 allele and males hemizygous for the Met108/158 allele.
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In the present study on VCFS patients, we utilize fMRI to asses COMT genotype and
gender-moderated effects on the neural activation that are elicited by viewing emotionally
salient images from the International Affective Picture System (IAPS) (Lang PJ et al. 1997).
Based on previous findings in both functional and neuroanatomical imaging studies, we
hypothesize that COMT genotype will have a sexually dimorphic effect on brain activation,
especially in areas such as the amygdala and other limbic structures that have been
previously shown to have differential activation during emotional processing in the general
population.
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2. Materials and Methods
2.1. Subjects

NIH-PA Author Manuscript
NIH-PA Author Manuscript

The procedures of this study were approved by the Institutional Review Board of the SUNY
Upstate Medical University and all participants provided informed consent. The sample of
43 subjects on whom we have imaging and genetic data is a subsample of 80 adolescents
with VCFS involved in a longitudinal study of biomarkers for psychosis in VCFS (Kates,
W.R. et al. 2004; Antshel, K.M. et al. 2005a; Antshel, K.M. et al. 2005b; Kates, W.R. et al.
2005; Antshel, K.M. et al. 2006; Kates, W.R. et al. 2006a; Kates, W.R. et al. 2006b;
Antshel, K.M. et al. 2007; Kates, W.R. et al. 2007a; Kates, W.R. et al. 2007b; Antshel,
K.M. et al. 2008a; Antshel, K.M. et al. 2008b). The subjects for the larger, longitudinal
study were recruited from the Center for the Diagnosis, Treatment, and Study of VCFS at
SUNY Upstate Medical University. Families who have a child with VCFS who is actively
followed through the Center were informed about the study by the center nurse practitioner.
In addition, the study was posted on the VCFS Educational Foundation website. A deletion
in the 22q11.2 region of the chromosome 22 was confirmed by fluorescence in situ
hybridization (FISH) in all the subjects included in this study. Only children with ages
between 9 and 15 years were included in the initial stage of the longitudinal study. Children
with an identifiable genetic disorder other than VCFS, paramagnetic implants, or with a
central nervous system (CNS) condition or conditions known to affect the CNS (i.e.
intractable seizure disorder, traumatic brain injury, fetal alcohol syndrome or effects,
elevated lead levels, or preterm birth (based on parent report)) were excluded from
participation.
Of the eighty participants in the longitudinal study, twelve subjects with a full scale IQ less
than 55 were excluded from the fMRI studies due to concern about performance. Three
subjects experienced anxiety while in the scanner and refused to participate in the fMRI
experiment. One subject was not scanned because of braces. Six subjects did not have
genotype data. Complete scans could not be acquired on eight subjects due to technical
difficulties during scanning. Finally, subjects with extensive interscan motion during the
fMRI experiment (more than 2mm translation and/or more than 2 degrees rotation over the
whole scan duration) were not included in the analysis (7 subjects, Val/Met=5/2).
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The resulting subsample used for the current analyses (43 subjects), which did not
significantly differ in IQ from the longitudinal study population, consisted of 25 adolescent
girls (mean age = 15.4, SD=2.2, range 11-21; mean IQ=72.6, SD=9.9, range 55-92) and 18
adolescent boys (mean age = 14.8, SD=2.2, range 12-20; mean IQ=68.5, SD=11.2, range
52-92). Eight (32%) girls and nine (50%) boys were hemizygous for the Met allele. While
the subjects hemizygous for the Val allele had significantly higher IQ scores than the Met
allele carriers (p=0.008, two tail t-test), there were no significant differences in IQ between
the female and male subjects. With the exception of two male subjects who were Asian (one
hemizygous for Met, the other for Val), all adolescents were Caucasian. At the time of their
participation, four (9.3%) subjects were taking anti-psychotic medication and eight (18.6%)
were taking other psychotropic medications, primarily stimulants, anti-depressants, antianxiety, or mood stabilizers (see Table 1 for gender/allele breakdown). During the
interviews, none of the subjects was found to have any drug or alcohol abuse. We conducted
chi-square analyses to compare the medication usage and psychiatric status of our four
groups, and found no significant differences for either set of analyses.
2.2. COMT Genotyping
Samples were genotyped in duplicate by sequencing or the ABI PRISM 5′ nuclease assay
TaqMan®). For sequencing, PCR products spanning the Val108/158Met variant were
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generated using the primers ValMet-F (5′ ctcatcaccatcgagatcaa) and ValMet-R (5′
gatgaccctggtgatagtgg) as previously described (Lachman, H.M. et al. 1996). For the ABI 5′
nuclease assay, TaqMan® primers and probes were designed using the Primer Express®
Oligo Design software v2.0 (ABI PRISM) or using the ABI Assays-By-Design service. PCR
amplification was carried out on 5–20 ng DNA using 1×TaqMan® universal PCR master
mix (No Amp-erase UNG), 900 nM forward and reverse primers, 200 nM of the FAM
labeled probe and 200 nM of the VIC labeled probe in a 5 ml reaction volume.
Amplification conditions on an ABI 9700 dual plate thermal cycle (Applied Biosystems,
Foster City, CA) were as follows: 1 cycle of 95°C for 10 min, followed by 50 cycles of 92°C
for 15 sec and 58°C for 1 min.
2.3. Imaging Study

NIH-PA Author Manuscript

Stimuli—For emotion induction, the subjects were presented with a variety of pictures from
the International Affective Picture System - IAPS (Lang, P.J. et al. 1993; Lang, P.J. et al.
1998), charged with neutral, negative, or positive emotional load. Pleasant, unpleasant, and
neutral cues were taken from IAPS (Lang, P.J. et al. 1993), in which images were
standardized across the dimensions of emotion, arousal, and valence (Lang, P.J. 1995). Each
emotional valence category was represented by 26 pictures. The stimuli were arranged in a
randomized order and were presented for 2500ms using an event-related design. During the
fMRI scans, the participants were instructed to passively view the stimuli, to avoid the
alteration of the brain activation pattern by the rating tasks (Taylor, S.F. et al. 2003).
However, in order to optimize attention to the task, the subjects were asked to button-press
when they saw an image that was upside down. The final image of the entire series was
presented upside down. The stimuli were preceded and followed at the beginning and the
end of the paradigm respectively by 20s resting periods with fixation crosses. Stimuli were
visually cued with a mirror attached to the head coil on a front-projection screen in the
scanner room. A laptop computer equipped with E-prime software (version 2) (Psychology
Software Tools, Pittsburgh, PA) generated the visual stimuli and controlled the experimental
parameters. After the fMRI acquisition, outside the scanner room, the subjects were asked to
go through the same sequence of stimuli and rank them on a scale from 1 through 8, with 1
standing for ‘very unpleasant’, 4 for ‘neutral’, and 8 for ‘very pleasant’. The response time
and the rating parameters were recorded for each stimulus.
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fMRI acquisition—Each subject was imaged once while performing the above paradigm
on a Philips Intera 1.5T MR scanner version release 11 (Philips Medical Systems, Best, The
Netherlands) equipped with a Phillips quadrature head coil. For fMRI, 25 slices were
acquired every 2.5s (4mm thickness, 1mm gap) using an FFE-EPI sequence (TR/TE =
2500ms/60ms, voxel size = 3.75×3.75, acq. matrix = 64×64×25 slices). A conventional 3D
scan was obtained for anatomic localization.
2.4. Data Analysis
Following image reconstruction and after discarding the first eight frames to allow for
stabilization of the magnetic field, the image data was transferred from the MRI scanned to
IBM compatible PC workstations via existing network connections. fMRI data were
analyzed offline using the Statistical Parametric Mapping-SPM5 software package
(Wellcome Department of Cognitive Neurology, 2005, London, UK,
http://www.fil.ion.ucl.ac.uk/spm/), running under a Windows version of Matlab2007b
(Mathworks, Inc., Natick, MA) on Centrino Duo based Dell computers. Statistical analysis
for behavioral data was conducted using the statistics analysis software package PASW
Statistics 17 (www.SPSS.com).
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Preprocessing of fMRI data—Images were visually inspected at intermediate stages of
the preprocessing to ensure the absence of ghosting, significant signal dropout, and any
other image processing artifacts. Preprocessing steps included: (1) Motion correction using
INRIalign, a motion correction algorithm unbiased by local signal changes (Freire, L. and
Mangin, J.F. 2001). (2) Spatial normalization of motion-corrected images into the standard
Montreal Neurological Institute space (Friston, K.J. et al. 1995), using a hybrid algorithm of
affine transformation and nonlinear warping, and the voxels were resampled at a resolution
of 3×3×3 mm3 using trilinear interpolation. (3) Gaussian spatial filtering with a full-width,
half maximum (FWHM) of 6 mm for group analysis.
First-level parametric fMRI analysis—We carried out first-level parametric analyses
individually for every subject utilizing the general linear model (GLM) in SPM5. The fMRI
data were analyzed as a time series modeled by a sine wave shifted by an estimate of the
hemodynamic response. A temporal smoothing kernel of 256 seconds was applied to
improve the signal-to-noise ratio of the data. Individual subject maps were created by using
one-sample t tests. We estimated parameters that reflected activation as (1) a contrast
between the tasks of viewing images with pleasant content and the ones with neutral content
(‘pleasant – neutral’) and (2) a contrast between the tasks of viewing images with unpleasant
content and the ones with neutral content (‘unpleasant – neutral’).
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Second-level analysis—The parameter estimates from the first-level analysis were
entered into a second level (random effects) full factorial analysis to test inferences about
differential activations between the two genotype groups and the gender interaction
(ValMale, ValFemale, MetMale, MetFemale). The three effects generated were: for main effect
of genotype [eg., 1 1 −1 −1], for main effect of gender [eg., 1 −1 1 −1], and for gene ×
gender interaction [eg., 1 −1 −1 1]. Guided by the results of previously published studies
(Smolka, M.N. et al. 2005; Kempton, M.J. et al. 2009) we performed ROI specific analyses
(Left/Right amygdala, Brodmann Areas (BA) 9, 24, 35, 36, 44 and 46) and we used an
uncorrected threshold of p=0.01 (voxelwise) to identify the regionally specific differences.
The ROIs were generated using WFU PickAtlas Tool Version 2.3 software (Maldjian, J.A.
et al. 2003) that generates ROI masks based on the Talairach Daemon database (Lancaster,
J.L. et al. 1997; Lancaster, J.L. et al. 2000). The resultant statistical maps were rendered
onto a three-dimensional standard brain. Statistically significant group differences (Tables 2
and 3) were reported as voxel-intensity t-values only for the voxels with a FDR (Benjamini,
Y. and Hochberg, Y. 1995) corrected p value less than 0.05 or those approaching
significance (<0.1). The coordinates reported for statistical maxima of neural activation are
in MNI(SPM) coordinate system. For anatomical label localization, statistical maxima of
activation were converted from the MNI(SPM) coordinates to conform to the standard
Talairach space (Talairach, J. and Tournoux, P. 1988) using BrainMap GingerALE
(www.brainmap.org) and Talairach Client (www.talairach.org).

3. Results and Discussion
3.1. Behavioral performance
ANOVA of the average pleasant ratings and neutral ratings indicated no significant
differences (p<0.05) by COMT, gender, or COMT-by-gender interaction. However, the
effect of COMT genotype (Val > Met) on unpleasant ratings approached significance (F
[1,1,1,31] = 3.58; p=0.068). We also observed a significant effect of COMT genotype (Val >
Met) on IQ scores (F [1,1,1,39] = 4.84; p=0.034), but no significant gender effect or COMTby-gender interaction.
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3.2. fMRI
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The genotype and gender distribution of the 43 subjects included in this experiment were as
follows: ValMale: N=9, ValFemale: N=17, MetMale: N=9, and MetFemale: N=8 (see Table 1).
We performed second-level (random effects) full factorial analyses across gender-by-COMT
levels.
Genotype Effect—In the ‘Unpleasant-Neutral’ contrast we observed an overall genotype
effect, where Met allele carriers exhibited significantly higher neural activation (pFDR=0.04)
in the left posterior mid-cingulate cortex (pMCC; BA posterior 24a’, posterior 24b’, 24d)
than Val allele carriers (see Table 3). No significant genotype effects (at pFDR<0.05) were
observed in the ‘Pleasant – Neutral’ contrast.
Gender Effect—In the ‘Pleasant-Neutral’ contrast we observed an overall gender effect,
where the female subjects showed increased cortical activation in the left anterior midcingulate gyrus (aMCC; BA anterior 24a’, b’, c’) (see Table 2). The analysis didn’t indicate
any significant gender effects (at pFDR<0.05) in the ‘Unpleasant – Neutral’ contrast.
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Genotype-by- Gender interaction—When we contrasted neural activation for pleasant
(vs. neutral) stimuli, we observed a gender-by-allele effect in the frontal system, specifically
the right pars opercularis (BA 44), where the female Val and the male Met subjects showed
significantly increased activation compared to the male Val and female Met subjects (see
Table 2 and Figure 1).
When we contrasted neural activation for unpleasant (vs. Neutral) stimuli, we observed a
gender-by-allele effect in the limbic system, where the Val male and the Met female subjects
demonstrated greater activation than Val female and Met male subjects (see Table 3 and
Figure 2) in the left amygdala, right parahippocampal gyrus (BA 35), and the left posterior
mid-cingulate cortex (pMCC; BA 24) (see Table 3).
3.3. Discussion
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To our knowledge, this is the first fMRI study to investigate the effect of the COMT
Val108/158Met polymorphism and gender on emotion induction in VCFS. We observed a
significant gender-by-allele interaction in neural function associated with processing both
pleasant and unpleasant stimuli. This suggests that in VCFS, the effect of the COMT
Val108/158Met polymorphism is moderated by gender during the processing of emotional
stimuli. These findings are consistent with our previous report of a gender-by-allele
interaction effect on neuroanatomic volumes of the prefrontal cortex (Kates, W.R. et al.
2006a).
Our results suggest that in VCFS, processing positive stimuli may be a function of gender
(as opposed to genotype) differences in that the combined group of girls activated the
anterior mid-cingulate region significantly more than combined group of boys. These results
are consistent with those of Hofer and colleagues who found gender-related neural responses
to positive and negative emotional stimuli in the general population (Hofer, A. et al. 2006).
In contrast, we found a gender-by-genotype interaction specific to the frontal lobe during the
processing of pleasant stimuli and specific to limbic and pMCC regions during the
processing of unpleasant stimuli. That is, we observed that Val females and Met males
recruited inferior frontal regions during the processing of pleasant stimuli, whereas Met
females and Val males recruited limbic regions during the processing of unpleasant stimuli.
This can be understood within the dual context of the hypothesized effect of COMT on brain
function and the hypothesized effect of estrogen on COMT function.
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In typical individuals, homozygosity for the Met allele is usually associated with optimal
functioning during cognitive tasks that recruit the prefrontal cortex (Egan, M.F. et al. 2001;
Malhotra, A.K. et al. 2002; Mattay, V.S. et al. 2003). Individuals with the Met-Met allele
degrade dopamine more slowly, increasing its availability in prefrontal synaptic clefts
(Lotta, T. et al. 1995), and optimizing efficiency during cognitive functioning. This is
attributable to the inverted U-shaped relationship between dopamine activity,
norepinephrine (NE) activity, and prefrontal function (Goldman-Rakic, P.S. et al. 2000;
Arnsten, A.F. 2007), which in typical individuals places homozygosity for the Met allele at
the top, “optimal point” of the inverted U. However, homozygosity for the Met allele in
typical individuals is also associated with increased neural activation of limbic regions
during emotion processing of negative stimuli (Smolka, M.N. et al. 2005), suggesting that
dopamine signaling in response to emotionally negative stimuli is enhanced in the limbic
regions of Met-homozygous individuals. Enhanced limbic signaling in Met-homozygous
individuals may over-burden the capacity of the prefrontal cortex to regulate limbic function
(Barnett, J.H. et al. 2007), putatively leading to decreased emotional resilience (Kempton,
M.J. et al. 2009) in these individuals, despite their optimized cognitive efficiency.
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Although previously published data on the effect of the COMT gene on cognitive function
in VCFS are not consistent, it has been hypothesized that in VCFS, the presence of only one
copy of the COMT gene results in greater cognitive vulnerability for individuals with the
low – activity Met allele (Meyer-Lindenberg, A. and Weinberger, D.R. 2006). This
hypothesis is based on the notion (Meyer-Lindenberg, A. and Weinberger, D.R. 2006) that
the inverted U-shaped relationship described above is shifted to the right in individuals with
VCFS, resulting in optimal functioning in VCFS individuals who are hemizygous for the
Val allele, and suboptimal functioning in VCFS individuals who are hemizygous for the Met
allele (since they are putatively exposed to relatively large amounts of dopamine in the
prefrontal cortex). The potential vulnerability conferred by the Met allele in VCFS may
extend to emotion processing as well (as is suggested by the findings by Gothelf, D et al.
(Gothelf, D. et al. 2005), which indicate that VCFS individuals with the Met allele were
more likely to exhibit severe psychiatric symptoms in late adolescence).
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As noted above, however, it has also been shown that estrogen down-regulates COMT
activity (Gogos, J.A. et al. 1998; Xie, T. et al. 1999; Jiang, H. et al. 2003), resulting in lower
COMT activity in women than men, despite the fact that both sexes have similar levels of
COMT protein and mRNA (Chen, J. et al. 2004; Tunbridge, E. et al. 2004) or higher in
women (Dempster, E. et al. 2006). Because estrogen inhibits COMT, the lowest
catecholamine (norepinephrine and dopamine) levels would be expected in Val108/158
males (whose male status and Val status together confer the highest level of COMT
activity), followed by intermediate catecholamine levels in Val108/158 females or
Met108/158 males (who possess either the higher activity COMT allele or lower estrogren
levels, but not both), and the highest catecholamine levels would be found in Met108/158
females (who possess both the low activity COMT allele and high estrogen levels). (See
Figure 3, which depicts the proposed shift in the inverted U for individuals with VCFS when
COMT genotype is considered).
As reviewed by Arnsten, the different levels of catecholamines that these gender-genotype
states produce can lead to disruption of cognitive processes, due to selective actions on
adrenergic alpha 1 and 2 receptors and dopaminergic D1 receptors (Arnsten, A.F. 2007).
Specifically, lower levels of norepinephrine are thought to “sharpen” the signals in brain
areas with high-affinity adrenergic alpha 2A receptors. Because alpha 2A receptors are
coupled to inhibitory G proteins, activation of these receptors inhibits the production of
cyclic AMP (cAMP) and reduces excess activity. In contrast, chronically high levels of
norepinephrine or dopamine (e.g., found in Met108/158 females) would increase binding to
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lower-affinity alpha 1 and beta 1 receptors as well as D1 receptors (all of which are coupled
to stimulatory G proteins and increase cAMP production). As Arnsten (2007) points out, this
excessive cAMP production and cellular activation actually impairs prefrontal cortical
function because the window of optimal dopamine stimulation is somewhat narrow
(Goldman-Rakic, P.S. et al. 2000; Takahashi, H. et al. 2005; Williams, G.V. and Castner,
S.A. 2006). Based on Arsten’s reasoning, we would predict that VCFS Val158 males exhibit
a lower efficiency for cognitive processing.
In contrast to the effects of high catecholamine levels on prefrontal cortical function, the
high cAMP levels and cellular activation produced by D1 activation, and alpha 1 and beta 1
activation are predicted by Arnsten (2007) to promote amygdala function. Thus, subjects
with higher catacholamines would be expected to perform better at determining the salience
or valence (positivity or negativity) of emotional stimuli and show greater amygdala
activation.
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Related to these points, a particularly noteworthy observation in the present study was the
shift in localization from anterior mid-cingulate cortex (aMCC) to posterior mid-cingulate
cortex (pMCC) activations when we probed for Gender specific effects in the Pleasant –
Neutral condition and Genotype specific effects (and Gender-by-Genotype interactions) in
the Unpleasant – Neutral condition. As already discussed, one inference from Arnsten’s
(2007) model is that the levels of catacholamines enhance activation of different receptor
subtypes (and thus potentially different cell populations and brain regions) in our paradigm.
Thus, the question arises whether the aMCC and pMCC express different adrenergic and
dopaminergic receptors which could account for the shift in activation in different states.
Support for this possibility comes from recent work mapping the alpha 1, alpha 2, and D1
receptor densities along the cingulate gyrus in postmortem human brain tissue (PalomeroGallagher, N. and Zilles, K. 2009). Interestingly, the pMCC was reported to contain 15%
more alpha 2 adrenergic receptors and 30% less D1 receptors than the aMCC. Thus, based
on Arnsten’s model, one might expect preferential activation of the pMCC in conditions of
low catecholamine drive, and preferential aMCC activation in conditions of high
catecholamine drive.
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Another possibility that might contribute to our observation of differential activation of
cingulate gyrus subregions, is the observation that previous functional imaging studies have
shown aMCC activation during elicitation of fear responses, while pMCC activation is
enhanced during elicitation of anger responses (reviewed in (Vogt, B. and Lane, R. 2009)).
Vogt and Lane (2009) further suggested that the patterns of differential activation were a
direct result of the differences in the relative strengths of connections that the aMCC and
pMCC have with the amygdala and subcortical noradrenergic nuclei. Based on the available
data, these authors concluded that the aMCC is involved in fear and avoidance behaviors,
while the pMCC is involved in coordinating skeletomotor and autonomic responses to
emotional stimuli. It is along these two dimensions that our subjects of different genotoypes
and genders would be expected to differ (i.e., fear and anger responsiveness). Interestingly
structural anomalies of the cingulate gyrus have also been implicated in VCFS. Specifically,
individuals with VCFS demonstrate bilateral volumetric reductions in the anterior cingulate
(DuFour et al, 2008), as well as cortical thinning in anterior and posterior cingulate (Bearden
et al., 2008). However, the extent to which these findings are moderated by either gender or
genotype status has not been explored.
Lastly, it should be noted that most of our participants are in mid-adolescence, a time during
which both estrogens and prefrontal dopamine/norepinephrine levels are likely increasing,
which may potentiate the effects of both estrogen and dopamine/norepinephrine on
modulation of emotional responsivity. Accordingly, the genotype-by-gender interactions
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that we have observed in brain function and brain structure (as our 2006 findings suggest
(Kates, W.R. et al. 2006a)) can be understood in the context of an interplay between COMT,
gender and development (Harrison & Tunbridge 2009).
3.4 Limitations
Since our study is limited to VCFS subjects, we cannot directly compare neuroactivation
differences between hemizygous and homozygous subjects, as well as to quantify the
differences in the ability to modulate emotions between hemizygous subjects with only one
copy of the COMT gene compared with the ones with two copies. While in our subsample
we did not find significant IQ differences between the female and male subjects, as reported
in Antshel et al. 2005a (on the sample from where our subsample was drawn), we have
found girls have slightly higher IQ. Accordingly, this can pose a potential limitation to our
findings. Moreover, the small size of the samples prevents us from examining the effects of
the presence of psychiatric disorder or the use of medication on the neural activation.
Additionally, one has to consider the fact that repeated presentation of emotionally salient
pictures could yield to habituation of activity of the ACC (Phan, K.L. et al. 2003) and the
amygdala (Zald, D.H. 2003). Despite these limitations however, our findings elucidate the
multifaceted interplay between the COMT polymorphism and gender that should be
considered in future studies of not only individuals with VCFS but also typically developing
youth and adults.
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Figure 1.

Region of neural activation in the right BA 44 (Pars opercularis, MNI(x,y,z)= (54,9,18)) that
presented significant (PFDR= 0.011, T=3.88, cluster size=24 voxels) COMT-by-Gender
interaction (‘ValFemale’ + ‘MetMale’) - (‘ValMale’ + ‘MetFemale’) during IAPS Emotion
Regulation tasks between Val108/158 and Met108/158 VCFS subjects in the ‘PleasantNeutral’ contrast.
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Figure 2.

Regions of neural activation that presented significant or approaching significance COMTby-Gender interaction (‘ValMale’ + ‘MetFemale’) - (‘ValFemale’ + ‘MetMale’) during IAPS
Emotion Regulation tasks between Val108/158 and Met108/158 VCFS subjects in the
‘Unpleasant-Neutral’ contrast. (A). Left Amygdala (MNI(x,y,z)= (−24, −9, −15),
PFDR=0.068, T= 3.1, cluster size=20 voxels); (B). Left BA 24 (Cingulate Gyrus,
MNI(x,y,z)= (−12, −18, 45), PFDR=0.043, T=3.6, cluster size=34 voxels); (C). Right BA 35
(Parahippocampal Gyrus, MNI(x,y,z)= (24, −30, −15), PFDR=0.044, T=3.24, cluster
size=16 voxels).
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Figure 3.

The proposed shift in the inverted U-shaped curve representing the relationship between
cortical dopamine/norepinephrine and emotion processing/regulation in individuals with
VCFS.
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Table 1

Number (percent) of participants with K-SADS-PL diagnoses or current medications, by genotype and gender
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Met Allele

Age (mean +/− SD)
Age range
Full scale IQ (mean, SD)

Val Allele

Females
(N=8)

Males
(N=9)

Females
(N=17)

Males
(N=9)

15.9 (+/−1.9)

14.3 (+/−1.2)

15.2 (+/−2.4)

15.4 (+/−3)

13.1-18.2

12.6-16.3

11.6-21.6

12.3-19.9

67.5 (+/−7.4)

65.4 (+/−9.8)

75 (+/−10.2)

71.5 (+/−12.2)

K-SADS-PL Diagnoses
Depression or Anxiety*
ADHD
Psychotic Symptoms**

4 (50)

1 (11)

2 (11.8)

1 (11)

1 (12.5)

3 (33)

4 (23.5)

3 (33)

2 (25)

4 (44)

2 (11.8)

1 (11)

1 (12.5)

1 (11)

2 (11.8)

Medications †
(Duration of treatment in years)
Anti-psychotics

NIH-PA Author Manuscript

0
(Mean=3.5 years, SD=1.9)
Other medications***

1 (12.5)

1 (11)

4 (23.5)

2 (22)

(Mean=2.5 years, SD=1.8)
*

Specific K-SADS-PL diagnoses from which this category was drawn includes major depressive disorder, generalized anxiety disorder, and
obsessive compulsive disorder
**

This category consists of endorsements of symptoms of hallucinations or delusions, at either the subthreshold or threshold level. Two of the nine
participants endorsed lifetime, but not present, symptoms. Only four participants of the nine participants were under antipsychotic medication
treatment.
***

Other medications include stimulants / atomoxotine, anti-depressants, anti-anxiety medications, and mood stabilizers

†

No substance abuse was identified in this sample (i.e. alcohol, drugs).
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Cingulate Gyrus

Limbic

Region
Pars opercularis

System

Frontal

Val M: −1 Met F: −1

Val F: 1 Met M: 1

Interaction Effect

Region

System

Females: 1 Males : −1

Overall Gender Effect

Pleasant - Neutral

44

BA

24

BA

Right

Side

Left

Side
6
12

−12
−12
33

39

z

54

x
9

y
18

z
3.88

T

MNI coordinates

y

x

MNI coodinates

0.011

48

cluster
size

24

cluster
size

0.046

0.046

PFDR

PFDR

3.57

3.81

T

Regions of neural activation during IAPS Emotion Regulation Tasks that significantly differed between Val108/158 and Met108/158 VCFS subjects in
the ‘Pleasant-Neutral’ contrast.
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Regions of neural activation during IAPS Emotion Regulation Tasks that significantly differed between Val108/158 and Met108/158 VCFS subjects in
the ‘Unpleasant’-‘Neutral’ contrast.
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